Dianthus Therapeutics CEO and President Garcia Marino exercised stock options on March 16, 2026 to acquire a total of 65,292 shares of common stock. This came from options for 59,700 shares at $6.70 per share and 5,592 shares at $17.88 per share. Following these exercises, Marino holds 65,292 common shares directly, while some option awards continue to vest over time according to their original schedules.
Dianthus Therapeutics CEO Garcia Marino reported an option exercise and related share sales. On March 12, 2026, he exercised stock options for 122,918 shares of common stock at an exercise price of $6.70 per share. The same day, he sold 122,918 shares of common stock in multiple open-market transactions at prices ranging from about $80.69 to $85.53 per share. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, he reported no directly held common shares and no remaining derivative position from this option grant.
Dianthus Therapeutics (DNTH) chief accounting officer Edward Carr exercised stock options and sold the resulting shares in a pre-planned series of trades. On March 12, 2026, he exercised options for 43,682 shares of common stock at exercise prices of $17.88, $21.77, and $22.07 per share.
The same day, he sold 43,682 common shares in multiple open-market transactions at weighted-average prices ranging from about $80.71 to $85.53 per share. A footnote states these sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating the trades were pre-scheduled rather than opportunistic.
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa exercised stock options for 33,830 shares of common stock and sold 33,830 shares in an open-market transaction. The sale was executed at a price of $81.48 per share and made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following these transactions, Randhawa held no shares of common stock directly, according to the filing.
Dianthus Therapeutics, Inc. entered an underwriting agreement to conduct a public offering of its common stock and pre-funded warrants. The company is issuing 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999 per warrant.
The underwriters received a 30-day option to buy up to 1,157,407 additional shares at the public offering price, less discounts, and exercised this option in full on March 11, 2026. Including this option exercise, Dianthus expects net proceeds of approximately $673.5 million after underwriting discounts, commissions and estimated expenses.
The pre-funded warrants are exercisable at any time after issuance with a $0.001 per share exercise price, subject to beneficial ownership limits of 4.99%, 9.99% or 19.99%, adjustable up to 19.99% with at least 61 days’ prior notice.
Dianthus Therapeutics is offering 7,313,582 shares of common stock and pre-funded warrants to purchase 402,468 shares of common stock at a public offering price of $81.00 per share. The offering is subject to an underwriters’ option to purchase up to an additional 1,157,407 shares.
Delivery is expected on March 12, 2026. Net proceeds are estimated at approximately $585.4 million (or approximately $673.5 million if the underwriters’ option is exercised in full). Proceeds are intended to advance clinical and preclinical development, commercial readiness, working capital and general corporate purposes; management will have broad discretion over use.
Dianthus Therapeutics filed a preliminary prospectus supplement to offer $400,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants to purchase common stock. The offering includes an underwriter option to purchase up to an additional $60,000,000.
The company’s common stock trades on Nasdaq under the symbol DNTH; the prospectus cites a reported sale price of $65.20 per share as of March 6, 2026. The prospectus states pro forma shares outstanding of 43,223,090 as of December 31, 2025. Net proceeds are intended to fund clinical and preclinical development, commercial readiness, working capital and general corporate purposes; management estimates cash will fund operations into late 2029.